PE20120517A1 - Inhibidores del virus de la hepatitis c - Google Patents
Inhibidores del virus de la hepatitis cInfo
- Publication number
- PE20120517A1 PE20120517A1 PE2011001733A PE2011001733A PE20120517A1 PE 20120517 A1 PE20120517 A1 PE 20120517A1 PE 2011001733 A PE2011001733 A PE 2011001733A PE 2011001733 A PE2011001733 A PE 2011001733A PE 20120517 A1 PE20120517 A1 PE 20120517A1
- Authority
- PE
- Peru
- Prior art keywords
- imidazol
- pyrrolidinyl
- cyclohexen
- hepatitis
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE s ES 0 O 1; L ES -L1-L2-; L1 Y L2 SON CICLOHEXILO, FENILO, CICLOHEXENO, ENTRE OTROS; Y E Y' SON O O NH; R1 ES H O C(O)Rx; R2 ES H O C(O)Ry; Rx Y Ry SON CICLOALQUILO C3-C8; ALQUILO C1-C10; ALCOXI C1-C10, ENTRE OTROS; R100 Y R110 SON H, ALQUILO C1-C10, CIANOALQUILO C1-C10 Y HALO. SON COMPUESTOS PREFERIDOS: ((1S)-1-(((2S)-2-(4-(4'-(2-((2S)-1-((2S)-2-((METOXICARBONIL)AMINO)-3-METILBUTANOIL-2-PIRROLIDINIL)-1H-IMIDAZOL-4-IL)-1,1'-BI(3-CICLOHEXEN-1-IL)-4-IL)-1H-IMIDAZOL-2-IL)-1-PIRROLIDINIL)CARBONIL)-2-METILPROPIL)CARBAMATO DE METILO, ((1S)-2-((2S)-2-(4-(4'-(2-((2S)-1-(N-(METOXICARBONIL)-L-ALANIL)-2-PIRROLIDINIL)-1H-IMIDAZOL-4-IL)-1,1'-BI(3-CICLOHEXEN-1-IL)-4-IL)-1H-IMIDAZOL-2-IL)-1-PIRROLIDINIL)-1-METIL-2-OXOETIL)CARBAMATO DE METILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA PROTEINA NS5A CODIFICADA POR EL VIRUS DE LA HEPATITIS C
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16457909P | 2009-03-30 | 2009-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120517A1 true PE20120517A1 (es) | 2012-05-09 |
Family
ID=42313493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001733A PE20120517A1 (es) | 2009-03-30 | 2010-03-29 | Inhibidores del virus de la hepatitis c |
Country Status (20)
Country | Link |
---|---|
US (2) | US20100249190A1 (es) |
EP (1) | EP2414352B1 (es) |
JP (1) | JP5612661B2 (es) |
KR (1) | KR20110134497A (es) |
CN (1) | CN102378762B (es) |
AR (1) | AR076170A1 (es) |
AU (1) | AU2010234861A1 (es) |
BR (1) | BRPI1014084A2 (es) |
CA (1) | CA2758047C (es) |
CL (1) | CL2011002453A1 (es) |
CO (1) | CO6361922A2 (es) |
EA (1) | EA021260B1 (es) |
ES (1) | ES2524542T3 (es) |
IL (1) | IL214939A0 (es) |
MX (1) | MX2011009644A (es) |
NZ (1) | NZ594981A (es) |
PE (1) | PE20120517A1 (es) |
TW (1) | TWI476190B (es) |
WO (1) | WO2010117704A1 (es) |
ZA (1) | ZA201106669B (es) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
RU2505540C2 (ru) * | 2008-12-23 | 2014-01-27 | Эббви Инк. | Антивирусные соединения |
EP2367823A1 (en) | 2008-12-23 | 2011-09-28 | Abbott Laboratories | Anti-viral compounds |
US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI438200B (zh) * | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102459165B (zh) * | 2009-04-15 | 2015-09-02 | Abbvie公司 | 抗病毒化合物 |
TWI629981B (zh) | 2009-05-13 | 2018-07-21 | 基利法瑪席特有限責任公司 | 抗病毒化合物 |
US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
SG10201702522UA (en) * | 2009-06-11 | 2017-05-30 | Abbvie Bahamas Ltd | Anti-viral compounds to treat hcv infection |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
EP2454254A2 (en) | 2009-07-16 | 2012-05-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of flavivirus infections |
SG178952A1 (en) | 2009-09-04 | 2012-04-27 | Glaxosmithkline Llc | Chemical compounds |
US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110137633A1 (en) * | 2009-12-03 | 2011-06-09 | Abbott Laboratories | Anti-viral compounds and methods of identifying the same |
EP2512480A4 (en) | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN104530079B (zh) * | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
SG188957A1 (en) | 2010-01-25 | 2013-05-31 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
WO2011109037A1 (en) | 2010-03-04 | 2011-09-09 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as inhibitors of hcv replication |
WO2011119853A1 (en) | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
US9127021B2 (en) | 2010-04-09 | 2015-09-08 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2011153396A1 (en) | 2010-06-04 | 2011-12-08 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
EP2585447A2 (en) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
WO2012006060A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
WO2012021704A1 (en) | 2010-08-12 | 2012-02-16 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
CN103153978A (zh) | 2010-08-17 | 2013-06-12 | 沃泰克斯药物股份有限公司 | 用于治疗或预防黄病毒科病毒感染的化合物和方法 |
RU2452735C1 (ru) * | 2010-11-30 | 2012-06-10 | Александр Васильевич Иващенко | Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения |
US20150031884A1 (en) * | 2010-12-15 | 2015-01-29 | Abbvie Inc. | Anti-viral compounds |
JP5906253B2 (ja) * | 2010-12-16 | 2016-04-20 | アッヴィ・インコーポレイテッド | 抗ウイルス性化合物 |
CA2822357A1 (en) | 2010-12-22 | 2012-06-28 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) * | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CN103687489A (zh) | 2011-05-18 | 2014-03-26 | 埃南塔制药公司 | 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法 |
CA2837481A1 (en) | 2011-05-27 | 2012-12-06 | Achillion Pharmaceuticals, Inc. | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections |
WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
WO2013016491A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Thiophene compounds |
NZ623396A (en) | 2011-09-16 | 2016-07-29 | Gilead Pharmasset Llc | Methods for treating hcv |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
MD596Z (ro) * | 2012-10-09 | 2013-09-30 | Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова | Metodă de tratament al hepatitei virale cronice C la copii |
LT2950786T (lt) | 2013-01-31 | 2020-03-10 | Gilead Pharmasset Llc | Dviejų antivirusinių junginių preparatų kompozicija |
US20150065439A1 (en) | 2013-02-28 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
EP3021845A1 (en) | 2013-07-17 | 2016-05-25 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
NZ716840A (en) | 2013-08-27 | 2017-06-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2017223532A1 (en) * | 2016-02-26 | 2018-08-30 | Jiangsu Hengrui Medicine Co., Ltd. | New toxin and method for preparing intermediate thereof |
CN107987083A (zh) * | 2017-11-24 | 2018-05-04 | 江苏亚盛医药开发有限公司 | 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5654451B1 (en) * | 1993-01-14 | 2000-02-22 | Magainin Pharma | Amino acids and peptides having modified c-terminals and modified n-terminals |
WO2006093867A1 (en) * | 2005-02-28 | 2006-09-08 | The Rockefeller University | Structure of the hepatitits c virus ns5a protein |
US20100158862A1 (en) * | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR20110098779A (ko) * | 2008-12-03 | 2011-09-01 | 프레시디오 파마슈티칼스, 인코포레이티드 | Hcv ns5a의 억제제 |
SG10201702522UA (en) * | 2009-06-11 | 2017-05-30 | Abbvie Bahamas Ltd | Anti-viral compounds to treat hcv infection |
-
2010
- 2010-03-24 TW TW099108734A patent/TWI476190B/zh not_active IP Right Cessation
- 2010-03-25 US US12/731,935 patent/US20100249190A1/en not_active Abandoned
- 2010-03-29 EP EP10714721.7A patent/EP2414352B1/en not_active Not-in-force
- 2010-03-29 CN CN201080015321.9A patent/CN102378762B/zh not_active Expired - Fee Related
- 2010-03-29 AU AU2010234861A patent/AU2010234861A1/en not_active Abandoned
- 2010-03-29 ES ES10714721.7T patent/ES2524542T3/es active Active
- 2010-03-29 EA EA201101240A patent/EA021260B1/ru not_active IP Right Cessation
- 2010-03-29 CA CA2758047A patent/CA2758047C/en not_active Expired - Fee Related
- 2010-03-29 BR BRPI1014084A patent/BRPI1014084A2/pt not_active IP Right Cessation
- 2010-03-29 NZ NZ594981A patent/NZ594981A/xx not_active IP Right Cessation
- 2010-03-29 JP JP2012503544A patent/JP5612661B2/ja not_active Expired - Fee Related
- 2010-03-29 PE PE2011001733A patent/PE20120517A1/es not_active Application Discontinuation
- 2010-03-29 KR KR1020117025610A patent/KR20110134497A/ko not_active Application Discontinuation
- 2010-03-29 MX MX2011009644A patent/MX2011009644A/es active IP Right Grant
- 2010-03-29 WO PCT/US2010/028999 patent/WO2010117704A1/en active Application Filing
- 2010-03-30 AR ARP100101039A patent/AR076170A1/es unknown
-
2011
- 2011-09-01 IL IL214939A patent/IL214939A0/en unknown
- 2011-09-12 ZA ZA2011/06669A patent/ZA201106669B/en unknown
- 2011-09-27 CO CO11126484A patent/CO6361922A2/es active IP Right Grant
- 2011-09-30 CL CL2011002453A patent/CL2011002453A1/es unknown
-
2012
- 2012-07-13 US US13/548,298 patent/US8822444B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW201038555A (en) | 2010-11-01 |
US8822444B2 (en) | 2014-09-02 |
AR076170A1 (es) | 2011-05-26 |
TWI476190B (zh) | 2015-03-11 |
CA2758047C (en) | 2016-05-17 |
ZA201106669B (en) | 2013-02-27 |
EA021260B1 (ru) | 2015-05-29 |
CL2011002453A1 (es) | 2012-03-02 |
MX2011009644A (es) | 2011-09-28 |
CO6361922A2 (es) | 2012-01-20 |
BRPI1014084A2 (pt) | 2016-04-19 |
US20100249190A1 (en) | 2010-09-30 |
ES2524542T3 (es) | 2014-12-10 |
JP5612661B2 (ja) | 2014-10-22 |
JP2012522056A (ja) | 2012-09-20 |
KR20110134497A (ko) | 2011-12-14 |
WO2010117704A1 (en) | 2010-10-14 |
AU2010234861A1 (en) | 2011-09-22 |
US20120277266A1 (en) | 2012-11-01 |
EP2414352B1 (en) | 2014-10-01 |
CN102378762B (zh) | 2014-10-29 |
EA201101240A1 (ru) | 2012-05-30 |
NZ594981A (en) | 2013-05-31 |
CA2758047A1 (en) | 2010-10-14 |
CN102378762A (zh) | 2012-03-14 |
EP2414352A1 (en) | 2012-02-08 |
IL214939A0 (en) | 2011-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120517A1 (es) | Inhibidores del virus de la hepatitis c | |
PE20120258A1 (es) | Derivados de bencimidazol-pirrolidina como inhibidores del virus de la hepatitis c | |
PE20121354A1 (es) | Inhibidores del virus de la hepatitis c | |
PE20120533A1 (es) | Inhibidores del virus de la hepatitis c | |
PE20160800A1 (es) | Combinacion de metil ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il-1-pirrolidinil)carbonil)-2-metilpropil)carbamato (daclatasvir) y n-(tert-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida (asunaprevir). | |
CY1113547T1 (el) | Διαδικασια συνθεσης ενωσεων χρησιμων στην αντιμετωπιση της ηπατιτιδας c | |
PE20080542A1 (es) | Inhibidores del virus de la hepatitis c | |
PE20120546A1 (es) | Inhibidores del virus de la hepatitis c | |
AR104566A2 (es) | Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo | |
PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20080072A1 (es) | Compuestos heterociclicos como inhibidores de proteasas serinas | |
PE20142185A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
PA8651001A1 (es) | Compuestos quimicos | |
NZ710567A (en) | Antiviral compounds | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
PE20070195A1 (es) | Inhibidores de histona deacetilasa | |
PE20142099A1 (es) | Derivados de sulfonamida | |
PE20061305A1 (es) | Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas | |
PE20131377A1 (es) | Triazina-oxadiazoles | |
PE20140038A1 (es) | Compuestos antivirales | |
PE20080677A1 (es) | Inhibidores de pirrolotriazina cinaza | |
EA200870358A1 (ru) | 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1 | |
MX2010004293A (es) | Derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nuevo uso principalmente como inhibidores de cmet. | |
AR051965A1 (es) | Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida | |
AR078542A1 (es) | Moduladores de gpr40 de pirrolidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |